Bayer in cancer collaboration
Finnish pharma company Orion and German healthcare giant Bayer have entered into an agreement for the development and commercialisation of a novel drug targeting prostate cancer.
Prostate cancer
PET/CT-specific radiopharmaceuticals for diagnosis and therapy
The multiple benefits of PET/CT are undisputed – one being the fact that radiopharmaceuticals, which are used at pico and nano levels – are not toxic.
NCBC to launch its International Delegate Program
The “State of Oncology 2013” report by the International Prevention Research Institute [IPRI] warns that the global number of new cancer cases will have doubled between 2008 and 2030.
Bringing innovative technologies together
Prostate cancer is the most common cancerous disease in men. Since magnetic resonance imaging (MRI) arrived the diagnostic capabilities for early detection have improved considerably, along with more selective prostate cancer treatment.
Advances in MRI/ultrasound fusion biopsy
Widely considered a safe procedure for targeted tissue sampling, the fusion of MR and ultrasound images for prostate biopsy purposes is quickly gaining ground among radiologists.
A clever(t) fusion for prostate diagnosis
Statistically speaking every fourth older German man suffers from prostate cancer with the mortality rate being 60,000 patients annually
Cancer has a smell and breathprint
Israel - Researchers are using breath-test technology to detect volatile organic compounds to tell whether a patient has stomach cancer.
UK researchers are working on a new MRI technique
UK researchers are working on a new MRI technique called hyperpolarised MRI – or Dynamic Nuclear Polarisation (DNP) – that can utilise more of the available nuclei than traditional MRI, helping to overcome some of its limitations by increasing sensitivity 10,000-fold or more. DNP is part of a longer-term aim to improve cancer mortality with the help of novel cancer imaging tools.
Tackling cancer information overload
Cancer specialists everywhere increasingly face new findings from molecular biology. Genetic profiling of tumours opens up entirely new perspectives on the disease. How to cope with and integrate new insights into cancer diagnosis and treatment was among key issues discussed at the 2nd European Forum on Oncology, held in Berlin this May
Hypofractionation
Making prostate cancer therapy more effective, more comfortable for patients and less expensive for society? Dose escalation, up to 80 Gy and above, may be necessary to successfully treat localised prostate cancer with radiotherapy (RT).
Researchers at Rigshospitalet find markers for testicular cancer
A team of researchers at Rigshospitalet has found a new and simple way of detecting testicular cancer before it starts. This discovery will benefit patients in both Denmark and abroad.
The 27th Annual EAU Congress
Around for almost 20 years, minimally invasive technologies such as laparoscopy and robot-assisted surgery are popular subjects – and aired again during the 27th EAU Congress held in February at the Palais des Congrès, Paris.
True values versus relative Measurements
Detecting prostate cancer with transrectal ultrasound using strain elastography is quite tricky: it works by applying pressure to the transducer to measure relative stiffness of tissue, Professor Correas points out and states that ‘more than 80 percent of prostate cancer develops in the peripheral zone which is against the rectal wall. If we apply pressure to this zone the deformation of the…
Urine Test Shows Prostate Cancer Risk
A new urine test can help aid early detection of and treatment decisions about prostate cancer, a study from the University of Michigan Comprehensive Cancer Center and the Michigan Center for Translational Pathology finds.
Ultra-high throughput and advanced testing methods
During the IFCC and EuroMedLab congress in Berlin, Beckmann Coulter launched into Europe its AU 5800, which, the firm reports, improves processing time compared to current systems and therefore meets the demands of ever faster workflow in clinical laboratories.
Hitachi Realtime Tissue Elastography (HI-RTE) with HI VISION Ascendus
HI-RTE allows the assessment and real-time colour display of tissue elasticity. The current generation ultrasound modality has proven applications in breast, prostate, thyroid and pancreatic disease and where diagnostic biopsy is indicated, HI-RTE allows more accurate localization and targeting of lesions.
Article • PSA
A two-step biomarker approach for prostate cancer
Prostate cancer is the most frequently diagnosed cancer in males in developed countries and the sixth leading cause of cancer death worldwide. One reason for the increase in diagnosis is the widespread uptake of the prostate-specific antigen (PSA) test, capable of detecting slow growing cancers that might otherwise go undetected.
A novel prostate disease marker and index show increased clinical accuracy
The role of prostate-specific antigen (PSA) in prostate cancer detection continued to command attention at during the annual congress of the European Association of Urology (EAU) in March.
ShearWave Elastography enters new applications and medical fields
In 2005, when they founded the French ultrasound company SuperSonic Imagine, Jacques Souquet PhD and Claude Cohen-Bacrie had to convince radiologists that they not only offered a new product but also a completely new ultrasound technology that could measure entirely new parameters.
Proton therapy
As one of the most advanced forms of precision radiotherapy, proton therapy enables the irradiation of tumours located deep within the body, in the proximity of critical organs, such as the optic nerve or some brain areas. The Institut Curie has renovated its proton therapy centre in Orsay near Paris. Since 1991, when the original centre opened, it has treated over 5,000 patients (4,000 for eye…
European cancer mortality predictions for the year 2011
There will be nearly 1.3 million deaths from cancer in Europe in 2011 according to predictions from a study published in the cancer journal, Annals of Oncology. The estimates, which have been reached after researchers used for the first time in Europe a new mathematical model for predicting cancer mortality, show a fall in overall cancer death rates for both men and women when compared to 2007.
Urine protein could pave the way for new prostate cancer test
Scientists from the Cancer Research UK Cambridge Research Institute and The Institute of Cancer Research (ICR) built on earlier genome-wide research to link a genetic change associated with prostate cancer risk to a significant reduction in the amount of a protein called microseminoprotein-beta (MSMB). The protein - which regulates prostate cell death - is produced by normal prostate cells –…
Urology Week calls for attention for prostate diseases
The European Association of Urology (EAU), the European knowledge centre of urology, and the national urological societies in Europe organise Urology Week annually – this year from 13 to 17 September - to inform people, especially men over 50, about urological diseases, their treatments and the work of the urologist.
Article • Prostate cancer risk assessment
Novel p2PSA marker more accurate than PSA testing
The effectiveness of PSA (prostate-specific antigen) screening on reducing prostate cancer mortality was given a boost in 2009 when the conclusive findings from the 10-year European Randomized Study of Screening for Prostate Cancer (ERSPC) -- the world’s largest prostate cancer screening study – were published.